Efficacy of Aflibercept versus Ranibizumab in the treatment of diabetic macular edema

QR Code

Efficacy of Aflibercept versus Ranibizumab in the treatment of diabetic macular edema

AIM: To observe the efficacy of aflibercept and ranibizumab in the treatment of diabetic macular edema(DME).METHODS: Patients with DME who visited the ophthalmology department of Xingtai People's Hospital for the first time from November 2019 to February 2020 were included in the study. They we...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Xiu-Xian Wang, Pei-Cheng Zhang, Jing Xie, Xiang-Rong Zuo
Format:	article
Langue:	EN
Publié:	Press of International Journal of Ophthalmology (IJO PRESS) 2021
Sujets:	diabetic macular edema aflibercept ranibizumab intravitreal injection effect Ophthalmology RE1-994
Accès en ligne:	https://doaj.org/article/aa28b6b9770a40eb851da109dcc786dd
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema
par: Fouda SM, et autres
Publié: (2017)

Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis
par: Pessoa B, et autres
Publié: (2021)

Intravitreal Aflibercept versus Laser Photocoagulation in Asian Patients with Diabetic Macular Edema: The VIVID-East Study
par: Chen YX, et autres
Publié: (2020)

Prolongation of injection interval after switching therapy from ranibizumab to aflibercept in Japanese patients with macular edema secondary to branch retinal vein occlusion
par: Tagami M, et autres
Publié: (2017)

Worsening anatomic outcomes following aflibercept for neovascular age-related macular degeneration in eyes previously well controlled with ranibizumab
par: Nudleman E, et autres
Publié: (2016)

Evaluation of contrast sensitivity and other visual function outcomes in diabetic macular edema patients following treatment switch to aflibercept from ranibizumab
par: Nixon DR, et autres
Publié: (2018)

Contralateral eye-to-eye comparison of intravitreal ranibizumab and a sustained-release dexamethasone intravitreal implant in recalcitrant diabetic macular edema
par: Thomas BJ, et autres
Publié: (2016)

Short-term outcomes in patients with branch retinal vein occlusion who received intravitreal aflibercept with or without intravitreal ranibizumab
par: Sakanishi Y, et autres
Publié: (2017)

Managing Diabetic Macular Edema in Clinical Practice: Systematic Review and Meta-Analysis of Current Strategies and Treatment Options
par: Veritti D, et autres
Publié: (2021)

Treatment of Macular Edema in Vascular Retinal Diseases: A 2021 Update
par: Andrzej Grzybowski, et autres
Publié: (2021)

Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion
par: Hall J
Publié: (2016)

Predictive Factors And Long-Term Visual Outcomes After Anti-Vascular Endothelial Growth Factor Treatment Of Retinal Angiomatous Proliferation
par: Maruyama-Inoue M, et autres
Publié: (2019)

Intravitreal ziv-aflibercept for macular edema following retinal vein occlusion
par: Paulose R, et autres
Publié: (2016)

Aflibercept versus Ranibizumab as a Second Line Therapy After Bevacizumab for Diabetic Macular Edema
par: Alsaedi NG, et autres
Publié: (2021)

One-Year Outcome of Aflibercept Intravitreal Injection in Vitrectomized Eyes with Diabetic Macular Edema
par: Tran THC, et autres
Publié: (2021)

The outcome of low-frequency intravitreal bevacizumab therapy for macular edema in retinal vein occlusions
par: Ivanovska Adjievska B, et autres
Publié: (2017)

Aflibercept for clinically significant diabetic macular edema: 12-month results in daily clinical practice
par: Campos Polo R, et autres
Publié: (2018)

EFFECT OF ANTI-VEGF THERAPY ON THE STRUCTURAL STATE OF THE RETINA IN DIABETIC MACULAR EDEMA
par: M. M. Bikbov, et autres
Publié: (2016)

Results of switchback from ranibizumab to aflibercept in patients with exudative age-related macular degeneration
par: Koike N, et autres
Publié: (2019)

Adding a Corticosteroid or Switching to Another Anti-VEGF in Insufficiently Responsive Wet Age-Related Macular Degeneration
par: Kaya C, et autres
Publié: (2019)

Evaluation of contrast sensitivity and other visual function outcomes in neovascular age-related macular degeneration patients after treatment switch to aflibercept from ranibizumab
par: Nixon DR, et autres
Publié: (2017)

One-year outcome of intravitreal aflibercept injection for age-related macular degeneration resistant to ranibizumab: rapid morphologic recovery and subsequent visual improvement
par: Hirakata T, et autres
Publié: (2016)

Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema
par: Fong AH, et autres
Publié: (2013)

Twelve-week dosing with Aflibercept in the treatment of neovascular age-related macular degeneration
par: Garweg JG
Publié: (2019)

Choroidal Blood Flow After Intravitreal Ranibizumab in Vitrectomized and Non-Vitrectomized Eyes with Diabetic Macular Edema
par: Pessoa B, et autres
Publié: (2021)

The 2-Year Leakage Index and Quantitative Microaneurysm Results of the RECOVERY Study: Quantitative Ultra-Widefield Findings in Proliferative Diabetic Retinopathy Treated with Intravitreal Aflibercept
par: Amy S. Babiuch, et autres
Publié: (2021)

Ranibizumab in monotherapy and combined with photodynamic therapy for retinal angiomatous proliferation
par: Arias L, et autres
Publié: (2016)

Intravitreal bevacizumab injections for diabetic macular edema – predictors of response: a retrospective study
par: Joshi L, et autres
Publié: (2016)

Two-year outcome of treat-and-extend aflibercept after ranibizumab in age-related macular degeneration and polypoidal choroidal vasculopathy patients
par: Azuma K, et autres
Publié: (2018)

Six-month results of intravitreal ranibizumab for macular edema after branch retinal vein occlusion in a single-center prospective study: visual outcomes and microaneurysm formation
par: Kawamura M, et autres
Publié: (2018)

Efficacy and safety of sustained-delivery fluocinolone acetonide intravitreal implant in patients with chronic diabetic macular edema insufficiently responsive to available therapies: a real-life study
par: Massin P, et autres
Publié: (2016)

Primary treatment of diabetic macular edema
par: Tushar M Ranchod, et autres
Publié: (2009)

Vitreous Reflux Frequency and Intraocular Pressure After First-Time Intravitreal Aflibercept Injections: Comparison of 30- and 32-Gauge Needles
par: Muto T, et autres
Publié: (2020)

Effect of prophylactic timolol 0.1% gel on intraocular pressure after an intravitreal injection of ranibizumab: a randomized study
par: Pece A, et autres
Publié: (2016)

Visual acuity loss associated with excessive “dry macula” in exudative age-related macular degeneration
par: Takahashi H, et autres
Publié: (2018)

Relationship between aqueous humor cytokine level changes and retinal vascular changes after intravitreal aflibercept for diabetic macular edema
par: Rodolfo Mastropasqua, et autres
Publié: (2018)

Dexamethasone implant in the management of diabetic macular edema from clinician’s perspective
par: Urbančič M, et autres
Publié: (2019)

Evaluation of the Safety of Bilateral Same-Day Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Agents: Experience of a Large Korean Retina Center
par: Jang K, et autres
Publié: (2020)

Baseline visual acuity strongly predicts visual acuity gain in patients with diabetic macular edema following anti-vascular endothelial growth factor treatment across trials
par: Dugel PU, et autres
Publié: (2016)

Prospective, Single-Center, Six-Month Study of Intravitreal Ranibizumab for Macular Edema with Nonproliferative Diabetic Retinopathy: Effects on Microaneurysm Turnover and Non-Perfused Retinal Area
par: Lee SJ, et autres
Publié: (2020)